Price movement over the last 24 hours
ADMA Biologics Inc vs Flagstar Bank NA — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Flagstar Bank NA trades at $14.43 (market cap $6.15B). The key difference: Flagstar Bank NA is far larger — about 2.9× ADMA Biologics Inc's market cap, and Flagstar Bank NA pays a 0.27% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FLG | |
|---|---|---|
Market Cap | $2.13B | $6.15B |
Sector | Health | Financials |
52-Week High | $20.38 | $15.28 |
52-Week Low | $7.60 | $10.72 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 0.27% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Flagstar Bank (FLG) trades at $14.84, up 1.71% today, showing technical bullish momentum with strong moving average signals. The company has delivered two consecutive quarterly earnings beats (Q4 2025 and Q1 2026) and recently announced a proprietary technology transformation. Despite negative profitability metrics, the stock trades below book value (P/B 0.81) and analysts maintain a 50/50 buy/hold split with a $16.94 consensus target.
FLG presents a turnaround story with improving fundamentals but carries execution risks. The bank's shift toward profitability and technology investments offers potential upside, though negative margins and high interest expenses remain concerns. With the current price below analyst targets, the stock offers value potential but requires careful monitoring of credit quality and operational improvements.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →